• Vaccine Ontology ID: VO_0004642
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Preparation: RVFV glycoprotein genes were incorporated into a nonreplicating complex adenovirus (CAdVax) vector platform to develop a RVFV vaccine (Holman et al., 2009).
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0011399
• Type: DNA vaccine
• Status: Research
• RVFVsSgp2 N protein gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pcDNA3.1/V5-His® TOPO (Lagerqvist et al., 2009)
• Immunization Route: Gene Gun

Mouse Response

• Vaccination Protocol: The mice were injected intraperitoneally (i.p.) with 1 × 10^8 PFU (1 × 10^10 total viral particles) of CAdVax-RVF or control CAdVax-D on week 0. CAdVax-D is a vector with a backbone identical to that of CAdVax-RVF that expresses dengue virus glycoproteins (22). Some mice also received booster vaccinations of the same dose on week 10 (Holman et al., 2009).
• Vaccine Immune Response Type: VO_0000287
• Challenge Protocol: Vaccinated and control animals were inoculated with 100 PFU of the ZH501 strain of RVFV by i.p. injection (Holman et al., 2009).
• Efficacy: Vaccinated mice were protected against lethal RVFV infection. Additionally, protection was elicited in mice despite preexisting immunity to the adenovirus vector (Holman et al., 2009).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Before immunisation the mice were thoroughly shaved on the abdomen and vaccinated with cDNA encoding the antigens using a gene-gun (Helios™, BioRad Laboratories). The cDNA was administrated four times with two to three week intervals. The primary immunisation was performed using four gene-gun cartridges and the following three boosters with two cartridges (Lagerqvist et al., 2009).
• Challenge Protocol: Mice were injected intraperitoneally (i.p.) with RVFV diluted in sterile PBS to a final volume of 100 μl (Lagerqvist et al., 2009).
• Efficacy: Even though complete protection was not achieved by genetic immunisation, four out of eight mice vaccinated with cDNA encoding the nucleocapsid protein displayed no clinical signs of infection after challenge. In contrast, all fourteen control animals displayed clinical manifestations of Rift Valley Fever after challenge (Lagerqvist et al., 2009).